Voices
Katy Beckermann: Early EV Rash May Be Associated With Better Survival in Urothelial Carcinoma
Katy Beckermann/LinkedIn

Katy Beckermann: Early EV Rash May Be Associated With Better Survival in Urothelial Carcinoma

Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:

“Early EV rash may be associated with response

  • EV-attributed skin toxicity: OS HR 0.46, PFS HR 0.60 at the 30-day landmark
  • Onset by day 15 carried the signal. Late rash did not.
  • High-grade rash did not predict worse survival Retrospective, and the rash group started healthier, ECOG 0 in 57% vs 33%.

Hope we continue to learn more as we understand dose intensity and response how we can best manage what can be severe skin toxicity. Topical and oral steroids, dose hold, and dose reductions.”

Title: Enfortumab Vedotin−Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma

Authors: Eudora Lee, Ralina Karagenova, Charles Lu, Parisa Farokh, Marjan Azin, Federico Repetto, Soma Jobbagy, Rosalynn Nazarian, Kerry Reynolds, Shadmehr Demehri, Philip Saylor, Lirit Fuksman, Yevgeniy Semenov

Read the Full Article on JAMA Dermatology

Katy Beckermann: Early EV Rash May Be Associated With Better Survival in Urothelial Carcinoma

Other posts featuring Katy Beckermann on OncoDaily.

 

cancer Charles Lu Eudora Lee Federico Repetto Katy Beckermann Kerry Reynolds Lirit Fuksman Marjan Azin OncoDaily Oncology Parisa Farokh Philip Saylor Ralina Karagenova Rosalynn Nazarian Shadmehr Demehri Soma Jobbagy urothelial carcinoma Yevgeniy Semenov